Tirzepatide Pricing Overview: What You Will Pay
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is sold under two brand names: Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). Both contain the same active ingredient at the same dosages, but their FDA indications and insurance coverage differ significantly.
In 2026, the retail prices for branded tirzepatide are:
Zepbound (2.5 mg–15 mg weekly, weight loss): $1,050–$1,250 per month
Mounjaro (2.5 mg–15 mg weekly, diabetes): $968–$1,150 per month
Compound tirzepatide: $75–$399 per month via telehealth providers
The cost gap between branded and compound tirzepatide mirrors what we see with semaglutide. Compound tirzepatide from reputable providers offers the same active ingredient at 80-90% less than the brand-name price. For context, the SURMOUNT-1 trial showed that tirzepatide at 15 mg produced an average 22.5% body weight reduction over 72 weeks — significantly more than semaglutide's 15% in comparable trials. [1]
Tirzepatide is dosed via subcutaneous injection once weekly, with a titration schedule starting at 2.5 mg for four weeks, then increasing in 2.5 mg increments every four weeks to the target maintenance dose (typically 10 mg or 15 mg for weight loss).